The news of QuidelOrtho exploring the sale of its transfusion medicine unit suggests a strategic move to streamline operations and focus on core business areas. This could be perceived positively by investors as it may improve financial efficiency and allow the company to allocate resources more effectively. The potential sale could also provide a one-time cash influx, which might be used for debt reduction, reinvestment in the business, or shareholder returns. However, the impact on the stock price will depend on further details such as the valuation of the unit and the terms of any potential deal.